BiotechTube

SY-5609 + Fulvestrant + Gemcitabine + Nab-paclitaxel

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumor

Conditions

Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer

Trial Timeline

Jan 23, 2020 → Mar 30, 2023

NCT ID
NCT04247126

About SY-5609 + Fulvestrant + Gemcitabine + Nab-paclitaxel

SY-5609 + Fulvestrant + Gemcitabine + Nab-paclitaxel is a phase 1 stage product being developed by Syros Pharmaceuticals for Advanced Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04247126. Target conditions include Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04247126Phase 1Completed

Competing Products

20 competing products in Advanced Solid Tumor

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Syros Pharmaceuticals

Tamibarotene + Placebo + AzacitidinePhase 3
69
Tamibarotene + Venetoclax + AzacitidinePhase 2
44
Tamibarotene + Azacitidine + DaratumumabPhase 2
44
Azacitidine + Tamibarotene + VenetoclaxPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Phase 1
25